diagnose disease Archives - Tamirna

15 01, 2024

Circulating endothelial extracellular vesicle signatures correspond with ICU requirement
Circulating endothelial extracellular vesicle signatures correspond with ICU requirement

biomarker, biomarkers, CoV-2, diagnose disease, exosomes, extracellular vesicle, microRNA services, microRNAs

Circulating endothelial extracellular vesicle signatures correspond with ICU requirement

2024-01-15T10:16:16+01:00January 15th, 2024|biomarker, biomarkers, CoV-2, diagnose disease, exosomes, extracellular vesicle, microRNA services, microRNAs|Comments Off on Circulating endothelial extracellular vesicle signatures correspond with ICU requirement

We want to draw your attention to the latest publication in cooperation with TAmiRNA – “Circulating endothelial extracellular vesicle signatures correspond with ICU requirement: an exploratory study in COVID-19 patients” published in Intensive Care Medicine Experimental. Using TAmiRNA’s expertise in the field of EV characterization, we found that endothelial EVs and associated miRNAs could be promising candidates for the diagnosis of patients with COVID-19. Click here to learn more about this service click here to read the paper

Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

2023-03-10T08:28:49+01:00January 30th, 2023|biomarkers, diagnose disease, extracellular vesicle, microRNA, platelet-associated miRNAs, smallRNA, thrombomiR, treatment monitoring|Comments Off on Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects

We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper

Biogenity Joins Forces with TAmiRNA

2023-03-10T08:29:26+01:00January 17th, 2023|biomarkers, diagnose disease, microRNA, NGS, smallRNA, treatment monitoring|Comments Off on Biogenity Joins Forces with TAmiRNA

The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release